Moreover, IACS‐010759 synergized not only with venetoclax to kill MYC/BCL2 DHL tumor cells in vivo and in vitro, as previously shown with tigecycline [289], but also with the MCL1 inhibitor S63845 against BCL2‐negative lymphoma cell lines [292]. Here, BCL2 is linked to neoplasm.